Assertio Holdings Inc (OQ:ASRT)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 100 S. Saunders Road, Suite 300
LAKE FOREST IL 60045
Tel: 1-510-7448000
Website: https://www.assertiotx.com
IR: See website
<
Key People
Heather L. Mason
Interim Chief Executive Officer, Director
Ajay Patel
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Sam Schlessinger
Senior Vice President, General Counsel, Executive Officer
Paul Schwichtenberg
Senior Vice President, Chief Commercial Officer
   
Business Overview
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company's primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Financial Overview
For the fiscal year ended 31 December 2023, Assertio Holdings Inc revenues decreased 3% to $152.1M. Net loss totaled $331.9M vs. income of $109.6M. Revenues reflect CAMBIA segment decrease of 67% to $8.1M, INDOCIN products segment decrease of 13% to $87.2M. Net loss reflects Selling, general and administrative expe increase of 79% to $68.5M (expense), Restructuring charges increase from $0K to $5.5M (expense).
Employees: 53 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $47.55M as of Dec 31, 2023
Annual revenue (TTM): $152.07M as of Dec 31, 2023
EBITDA (TTM): $44.50M as of Dec 31, 2023
Net annual income (TTM): -$331.94M as of Dec 31, 2023
Free cash flow (TTM): $48.56M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 94,995,823 as of Mar 5, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.